8:34 am Corcept Therapeutics reports interim analysis of data from Phase 3 Trial of Mifepristone for the Treatment of psychotic depression fails to demonstrate efficacy with statistical significance (stock halted)
View todays social media effects on CORT
View the latest stocks trending across Twitter. Click to view dashboard
See who Corcept is hiring next, click here to view
